HCRA supports research collaborations that promote innovation across the translational spectrum, with the aim of developing a better understanding of cancer. With expertise spanning from prevention strategies through to improved methods of diagnosis and the development of more personalised therapies for the treatment of cancer, our researchers aim to improve health outcomes for people at risk of developing or dying of cancer.
At HCRA we are proud to represent and work with a diverse group of highly experienced researchers and clinicians in all areas of translational research. You can find out more about our members and the work they conduct in their research areas by clicking on the links below.
HCRA has streamlined its research efforts into four main Flagship programs: Biomarkers and Targeted Therapies (BTT); Radiation Oncology, Cancer Imaging & Technology (ROCIT), Implementation Science and Impact (ISI) and the Clinical Cancer Research Network (CCRN).
View more information about each Flagship.
The primary objective of the FLG is to build research capacity, foster collaboration and develop support structures for early and mid-career cancer researchers (EMCRs). The FLG program is a pivotal HCRA knowledge dissemination platform for educating the next generation of clinicians and researchers towards leadership.
Read more about the FLG and the opportunities available to members.
The HCRA Consumer Advisory Panel (CAP) is a group of community volunteers who from time to time are invited to add value to the work of our members. Consumer advocates play a fundamental role in health research, offering a unique perspective to health and cancer care that can help inform research projects in many ways.
Learn more about CAP.
Collecting and preserving tissue from local residents with cancer, the Hunter Cancer Biobank (HCB) stores patient samples, annotated with clinical information, to provide a resource for scientific and medical researchers looking into the causes, development, diagnosis and treatment of disease.